Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 313

1.

[Eosinophilic Esophagitis Update: New Guidelines of the European Study Group EUREOS].

Miehlke S, Schlag C, Storr M, von Arnim U.

Laryngorhinootologie. 2019 Nov;98(11):764-775. doi: 10.1055/a-0960-6553. Epub 2019 Nov 18. German.

PMID:
31739353
2.

Ein Therapie-Algorithmus bei Reizmagen.

Storr M.

MMW Fortschr Med. 2019 Oct;161(18):38. doi: 10.1007/s15006-019-1003-9. Review. German. No abstract available.

PMID:
31631306
3.

Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43].

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2019 Nov 5;862:172656. doi: 10.1016/j.ejphar.2019.172656. Epub 2019 Sep 10. No abstract available.

PMID:
31519354
4.

Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders.

Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, Congly SE.

J Can Assoc Gastroenterol. 2019 Apr;2(1):37-43. doi: 10.1093/jcag/gwy064. Epub 2018 Nov 8. No abstract available.

5.

The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany.

Peri R, Aguilar RC, Tüffers K, Erhardt A, Link A, Ehlermann P, Angeli W, Frank T, Storr M, Glück T, Sturm A, Rosien U, Tacke F, Bachmann O, Solbach P, Stallmach A, Goeser F, Vehreschild MJ; German Clinical Microbiome Study Group (GCMSG).

United European Gastroenterol J. 2019 Jun;7(5):716-722. doi: 10.1177/2050640619839918. Epub 2019 Mar 21.

6.

The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome.

Szymaszkiewicz A, Malkiewicz A, Storr M, Fichna J, Zielinska M.

J Physiol Pharmacol. 2019 Feb;70(1). doi: 10.26402/jpp.2019.1.01. Epub 2019 Apr 20. Review.

7.

Retention of beneficial molecules and coagulation factors during haemodialysis and haemodiafiltration.

Voigt M, Gebert M, Haug U, Hulko M, Storr M, Boschetti-de-Fierro A, Beck W, Krause B.

Sci Rep. 2019 Apr 23;9(1):6370. doi: 10.1038/s41598-019-42783-w.

8.

Interaction of hydrogen with actinide dioxide (111) surfaces.

Pegg JT, Shields AE, Storr MT, Scanlon DO, de Leeuw NH.

J Chem Phys. 2019 Apr 7;150(13):134701. doi: 10.1063/1.5087577.

PMID:
30954055
9.

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.

Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M.

Lancet Haematol. 2019 Apr;6(4):e217-e228. doi: 10.1016/S2352-3026(19)30014-6. Epub 2019 Mar 11.

PMID:
30872075
10.

[Patient perception and approval of fecal microbiota transplantation (FMT) as an alternative treatment option for ulcerative colitis].

Roggenbrod S, Schuler C, Haller B, Sohn M, Storr M, Schepp W, Gundling F.

Z Gastroenterol. 2019 Mar;57(3):296-303. doi: 10.1055/a-0821-7166. Epub 2019 Mar 12. German.

PMID:
30861553
11.

Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.

Szymaszkiewicz A, Storr M, Fichna J, Zielinska M.

Neurogastroenterol Motil. 2019 Apr;31(4):e13526. doi: 10.1111/nmo.13526. Epub 2018 Dec 14. Review.

PMID:
30549162
12.

Magnetic structure of UO2 and NpO2 by first-principle methods.

Pegg JT, Shields AE, Storr MT, Wills AS, Scanlon DO, de Leeuw NH.

Phys Chem Chem Phys. 2019 Jan 2;21(2):760-771. doi: 10.1039/c8cp03581d.

PMID:
30547167
13.

Reizdarmtherapie ohne Medikamente.

Storr M.

MMW Fortschr Med. 2018 Dec;160(21-22):36. doi: 10.1007/s15006-018-1226-1. German. No abstract available.

PMID:
30542869
14.

[Interpretation und performance of high-resolution esophageal manometry: Recommendations of the German Association of Neurogastroenterology and Motility (DGNM) and the German Association of Gastroenterology, Digestive and Metabolic Diseases (DGVS)].

Keller J, Fox MR, Allescher HD, Frieling T, Fuchs KH, Goebel-Stengel M, Pehl C, Schirra J, van der Voort I, Storr M.

Z Gastroenterol. 2018 Nov;56(11):1378-1408. doi: 10.1055/a-0713-0944. Epub 2018 Nov 12. German.

PMID:
30419581
15.

Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration.

Leypoldt JK, Storr M, Agar BU, Boschetti-de-Fierro A, Bernardo AA, Kirsch AH, Rosenkranz AR, Krieter DH, Krause B.

Nephrol Dial Transplant. 2019 May 1;34(5):870-877. doi: 10.1093/ndt/gfy304.

PMID:
30307514
16.

Membrane innovation: closer to native kidneys.

Storr M, Ward RA.

Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii22-iii27. doi: 10.1093/ndt/gfy228. Review.

17.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17. Erratum in: Eur J Pharmacol. 2019 Nov 5;862:172656.

PMID:
30121173
18.

A Double-Blind Randomized Controlled Trial of High Cutoff Versus Standard Hemofiltration in Critically Ill Patients With Acute Kidney Injury.

Atan R, Peck L, Prowle J, Licari E, Eastwood GM, Storr M, Goehl H, Bellomo R.

Crit Care Med. 2018 Oct;46(10):e988-e994. doi: 10.1097/CCM.0000000000003350.

PMID:
30074491
19.

Hidden magnetic order in plutonium dioxide nuclear fuel.

Pegg JT, Shields AE, Storr MT, Wills AS, Scanlon DO, de Leeuw NH.

Phys Chem Chem Phys. 2018 Aug 15;20(32):20943-20951. doi: 10.1039/c8cp03583k.

PMID:
30067255
20.

[Psychosomatics in gastroenterology - statement of the Work Group for Psychosomatics in Gastroenterology of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)].

Auer PG, Enck P, Häuser W, Stengel A, Storr M, Langhorst J; AG Psychosomatik in der Gastroenterologie der DGVS.

Z Gastroenterol. 2018 Jun;56(6):684-689. doi: 10.1055/a-0599-1248. Epub 2018 Jun 11. German.

PMID:
29890563
21.

Understanding students' and clinicians' experiences of informal interprofessional workplace learning: an Australian qualitative study.

Rees CE, Crampton P, Kent F, Brown T, Hood K, Leech M, Newton J, Storr M, Williams B.

BMJ Open. 2018 Apr 17;8(4):e021238. doi: 10.1136/bmjopen-2017-021238.

22.
23.

Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice.

Szymaszkiewicz A, Zielinska M, Li K, Ramanathan M, Alam S, Hou DR, Fichna J, Storr M.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):435-444. doi: 10.1007/s00210-018-1465-9. Epub 2018 Feb 5.

PMID:
29404698
24.

Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro.

Willy K, Girndt M, Voelkl J, Fiedler R, Martus P, Storr M, Schindler R, Zickler D.

Blood Purif. 2018;45(1-3):131-138. doi: 10.1159/000484925. Epub 2017 Dec 22.

PMID:
29402827
25.

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.

Binienda A, Storr M, Fichna J, Salaga M.

Curr Drug Targets. 2018;19(15):1774-1781. doi: 10.2174/1389450119666171227225408. Review.

PMID:
29284389
26.

FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.

Mosińska P, Jacenik D, Sałaga M, Wasilewski A, Cygankiewicz A, Sibaev A, Mokrowiecka A, Małecka-Panas E, Pintelon I, Storr M, Timmermans JP, Krajewska WM, Fichna J.

Neurogastroenterol Motil. 2018 May;30(5):e13272. doi: 10.1111/nmo.13272. Epub 2017 Dec 20.

PMID:
29266569
27.

Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression.

Zickler D, Luecht C, Willy K, Chen L, Witowski J, Girndt M, Fiedler R, Storr M, Kamhieh-Milz J, Schoon J, Geissler S, Ringdén O, Schindler R, Moll G, Dragun D, Catar R.

Nephrol Dial Transplant. 2018 Apr 1;33(4):574-585. doi: 10.1093/ndt/gfx316.

PMID:
29228352
28.

How do professional Australian Football League (AFL) players utilise social media during periods of injury? A mixed methods analysis.

Nankervis B, Ferguson L, Gosling C, Storr M, Ilic D, Young M, Maloney S.

J Sci Med Sport. 2018 Jul;21(7):681-685. doi: 10.1016/j.jsams.2017.10.034. Epub 2017 Nov 7.

PMID:
29174299
29.

[Four reasons for the bloated abdomen of your patient].

Storr M, Waggershauser C.

MMW Fortschr Med. 2017 Nov;159(20):43-48. doi: 10.1007/s15006-017-9601-x. Review. German. No abstract available.

PMID:
29159608
30.

[Eosinophilic Esophagitis Update: New Guidelines of the European Study Group EUREOS].

Miehlke S, Schlag C, Storr M, Arnim UV.

Z Gastroenterol. 2018 Feb;56(2):139-150. doi: 10.1055/s-0043-121349. Epub 2017 Nov 9. German.

PMID:
29121691
31.

Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis.

Trojanowicz B, Ulrich C, Fiedler R, Martus P, Storr M, Boehler T, Werner K, Hulko M, Zickler D, Willy K, Schindler R, Girndt M.

Nephrol Dial Transplant. 2018 Jan 1;33(1):34-43. doi: 10.1093/ndt/gfx206.

PMID:
28992224
32.

Membrane Innovation in Dialysis.

Boschetti-de-Fierro A, Beck W, Hildwein H, Krause B, Storr M, Zweigart C.

Contrib Nephrol. 2017;191:100-114. doi: 10.1159/000479259. Epub 2017 Sep 14. Review.

PMID:
28910794
33.

In vitro benchmark of cytokine removal by dialyzers with various permeability profiles.

Hulko M, Speidel R, Gauss J, Storr M, Krause B.

Int J Artif Organs. 2017 Oct 27;40(11):615-621. doi: 10.5301/ijao.5000639. Epub 2017 Aug 11.

PMID:
28862721
34.

Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast.

Abdel-Aziz H, Kelber O, Lorkowski G, Storr M.

Planta Med. 2017 Oct;83(14-15):1130-1140. doi: 10.1055/s-0043-116852. Epub 2017 Aug 31. Review.

35.

Removal of Cell-Activating Substances Using Dialyzers With Various Permeability Profiles.

Latosinska A, Hulko M, Speidel R, Mischak H, Storr M, Krause B.

Artif Organs. 2018 Jan;42(1):78-87. doi: 10.1111/aor.12952. Epub 2017 Jul 26.

PMID:
28744941
36.

Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

Salaga M, Zatorski H, Zielińska M, Mosinska P, Timmermans JP, Kordek R, Storr M, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Oct;390(10):1015-1027. doi: 10.1007/s00210-017-1402-3. Epub 2017 Jul 14.

PMID:
28710683
37.

Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT).

Bashashati M, Fichna J, Piscitelli F, Capasso R, Izzo AA, Sibaev A, Timmermans JP, Cenac N, Vergnolle N, Di Marzo V, Storr M.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13148. Epub 2017 Jul 11.

PMID:
28695708
38.

Medium cut-off membranes - closer to the natural kidney removal function.

Zweigart C, Boschetti-de-Fierro A, Hulko M, Nilsson LG, Beck W, Storr M, Krause B.

Int J Artif Organs. 2017 Jul 5;40(7):328-334. doi: 10.5301/ijao.5000603. Epub 2017 May 26. No abstract available.

39.

Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal.

Fabisiak A, Włodarczyk J, Fabisiak N, Storr M, Fichna J.

J Neurogastroenterol Motil. 2017 Jul 30;23(3):341-348. doi: 10.5056/jnm16203. Review.

40.

In Vitro Dialysis of Cytokine-Rich Plasma With High and Medium Cut-Off Membranes Reduces Its Procalcific Activity.

Willy K, Hulko M, Storr M, Speidel R, Gauss J, Schindler R, Zickler D.

Artif Organs. 2017 Sep;41(9):803-809. doi: 10.1111/aor.12884. Epub 2017 May 19.

PMID:
28524237
41.

Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults.

Lucendo AJ, Molina-Infante J, Arias Á, von Arnim U, Bredenoord AJ, Bussmann C, Amil Dias J, Bove M, González-Cervera J, Larsson H, Miehlke S, Papadopoulou A, Rodríguez-Sánchez J, Ravelli A, Ronkainen J, Santander C, Schoepfer AM, Storr MA, Terreehorst I, Straumann A, Attwood SE.

United European Gastroenterol J. 2017 Apr;5(3):335-358. doi: 10.1177/2050640616689525. Epub 2017 Jan 23. Review.

42.

Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.

Madisch A, Vinson BR, Abdel-Aziz H, Kelber O, Nieber K, Kraft K, Storr M.

Wien Med Wochenschr. 2017 May;167(7-8):160-168. doi: 10.1007/s10354-017-0557-3. Epub 2017 Apr 19. Review.

43.

[Current treatment of dyspepsia in primary care].

Waggershauser CH, Allescher HD, Storr M.

MMW Fortschr Med. 2017 Apr;159(7):46-54. doi: 10.1007/s15006-017-9044-4. German. No abstract available.

PMID:
28417420
44.

Remote-online case-based learning: A comparison of remote-online and face-to-face, case-based learning - a randomized controlled trial.

Nicklen P, Keating JL, Paynter S, Storr M, Maloney S.

Educ Health (Abingdon). 2016 Sep-Dec;29(3):195-202. doi: 10.4103/1357-6283.204213.

45.

Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome.

Wasilewski A, Lewandowska U, Mosinska P, Watala C, Storr M, Fichna J, Venkatesan T.

Am J Gastroenterol. 2017 Jun;112(6):933-939. doi: 10.1038/ajg.2017.73. Epub 2017 Mar 28.

PMID:
28349993
46.

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Hasenoehrl C, Storr M, Schicho R.

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):329-337. doi: 10.1080/17474124.2017.1292851. Epub 2017 Feb 16. Review.

47.

Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists.

Mosińska P, Zatorski H, Storr M, Fichna J.

J Neurogastroenterol Motil. 2017 Apr 30;23(2):171-179. doi: 10.5056/jnm16183. Review.

48.

G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain.

Zielińska M, Fichna J, Bashashati M, Habibi S, Sibaev A, Timmermans JP, Storr M.

Neurogastroenterol Motil. 2017 Jul;29(7). doi: 10.1111/nmo.13025. Epub 2017 Feb 12.

PMID:
28191706
49.

Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.

Taschler U, Hasenoehrl C, Storr M, Schicho R.

Handb Exp Pharmacol. 2017;239:343-362. doi: 10.1007/164_2016_105. Review.

PMID:
28161834
50.

Detection of Free Advanced Glycation End Products in Vivo during Hemodialysis.

Hohmann C, Liehr K, Henning C, Fiedler R, Girndt M, Gebert M, Hulko M, Storr M, Glomb MA.

J Agric Food Chem. 2017 Feb 1;65(4):930-937. doi: 10.1021/acs.jafc.6b05013. Epub 2017 Jan 23.

PMID:
28112514

Supplemental Content

Support Center